Previous 10 | Next 10 |
WARREN, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today receipt of the fi...
Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%,...
Phoenix New Media (FENG) +62% after announcing special distribution.Hudson Capital (HUSN) +37%.Aptevo Therapeutics (APVO) +31% following a disclosure that 42.5% shareholder Tang Capital Partners offered to buy the remaining shares for $50/share in cash.Corcept Therapeutics...
Gainers: [[SONO]] +22.6%. [[LB]] +14.3%. [[LOW]] +8.9%. [[FCEL]] +8.6%. [[AQST]] +6.9%.Losers: [[EVGN]] -14.9%. [[PNNT]] -7.3%. [[ZTO]] -5.8%. [[CD]] -5.5%. [[GPRO]] -5.1%. For further details see: SONO, CD, ZTO and LB among after-hours movers
Aquestive Therapeutics (AQST) +11.6% after-hours as it completed its Type A meeting with the Food and Drug Administration confirming a pathway for resubmission for approval of the company's Libervant (diazepam) Buccal Film drug candidate for management of seizure clusters.Based on the FD...
FDA confirms issues identified in FDA Complete Response Letter (CRL) of September 25, 2020 may be addressed by utilizing modeling and simulations for an updated dosing regimen FDA recommends and Aquestive agrees to a follow-up FDA meeting prior to resubmission WARREN, N.J., No...
Gainers: [[VIST]] +13.1%. [[ZM]] +10.8%. [[YALA]] +8.1%. [[MTOR]] +5.9%. [[WRE]] +5.1%.Losers: [[OLED]] -29.9%. [[PTEN]] -10.1%. [[LASR]] -5.0%. [[AQST]] -4.1%. [[GNLN]] -3.5%. For further details see: VIST, ZM, OLED and LASR among after-hours movers
Aquestive Therapeutics, Inc. (AQST) Q3 2020 Results Earnings Conference Call November 05, 2020, 08:00 AM ET Company Participants Stephanie Carrington - IR, Westwicke Keith Kendall - President and Chief Executive Officer John Maxwell - SVP and Chief Financial Officer Dan Barber - SVP and Chief...
Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q3 2020 Earnings Call Nov 05, 2020 , 8:00 a.m. ET Operator Continue reading For further details see: Aquestive Therapeutics, Inc. (AQST) Q3 2020 Earnings Call Tran...
Aquestive Therapeutics (AQST): Q3 GAAP EPS of -$0.49 misses by $0.04.Revenue of $8.3M (-33.1% Y/Y) misses by $0.42M.FY20 guidance: Total revenues of ~$42M-$46M vs consensus of $47.3M; Non-GAAP adjusted gross margins of ~70%-75%; Non-GAAP adjusted EBITDA loss of ~$38M-$42M; Cash burn of ~...
News, Short Squeeze, Breakout and More Instantly...
Aquestive Therapeutics Inc. Company Name:
AQST Stock Symbol:
NASDAQ Market:
Aquestive Therapeutics Inc. Website:
Meets primary study endpoints with pharmacokinetics (PK) comparable whether Anaphylm is administered by subjects or by healthcare providers (HCPs) Final supportive study, the Oral Allergy Syndrome (OAS) challenge study, currently enrolling Continues to anticipate requesting a pr...
WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolog...